Altimmune, Inc. — Director's Dealing 2021

Nov 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2021-11-19

Reporting Person: Drutz David (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-19	Common Stock, par value $0.0001	M	70	$2.40	Acquired	17673	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-19	Stock Options (option to buy)	$2.40	M	70	Disposed	2021-12-03	Common Stock, par value $0.0001 (70)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.0001	333	Indirect

Footnotes

F1: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.

F2: This option was previously reported as covering 2,090 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018.

F3: This option is fully vested and exercisable as of the date hereof.